Taken altogether, these results suggest that aberrant expression of components of the IGF1R-mediated pathway is associated with better clinical outcomes in women with hormone receptor positive, HER2 negative, node positive early breast cancer. This evidence concerns the gene ERBB2 and breast cancer.